ALI HEALTH's stock price surged 5.17% during intraday trading on Monday, extending its recent upward trend in the market.

The significant price movement appears to be driven by the continued intensification of the company's innovative drug launch platform effect. Multiple pharmaceutical companies have recently chosen ALI HEALTH as the exclusive online launch channel for their new drugs, including Hengrui Medicine's Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout), Yangtze River Pharmaceuticals' Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction), and Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch.

These consecutive launches reinforce ALI HEALTH's positioning as a premier online platform for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities within the innovative drug commercialization chain. The company's management has previously guided for FY2027 revenue growth of 10% to 15%, identifying innovative drug categories as the core growth driver for the business.